For example, predicted treatment response based on PD‐L1 IHC and tumor mutation burden (TMB) assessment is not always definitive because of the lack of useable tissue and the low percentage of tumor cells in affected samples; despite some patients having high TMB and PD‐L1‐positive cells, immunotherapy may also fail. This evidence concerns the gene CD274 and neoplasm.